Tara Gregory
YOU?
Author Swipe
View article: BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1-3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results
BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1-3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results Open
Introduction The increasing use of quadruplet induction and monoclonal antibody-based maintenance therapies in the management of MM results in the disease becoming refractory to existing therapy classes relatively early in its course. Ther…
View article: Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network
Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network Open
We analyzed access barriers to anti-CD19+ chimeric antigen receptor T cells (CARTs) for non-Hodgkin lymphoma (NHL) within a community-based transplant and cell therapy network registry. A total of 357 intended recipients for approved anti-…
View article: Bendamustine Versus Fludarabine and Cyclophosphamide for Lymphodepletion Prior to CAR-T Therapy
Bendamustine Versus Fludarabine and Cyclophosphamide for Lymphodepletion Prior to CAR-T Therapy Open
Background As CAR-T treatment volumes and approved indications rapidly expand, identifying optimal lymphodepleting chemotherapy (LDC) regimens is an urgent and unmet need. A combination of fludarabine and cyclophosphamide (flu/cy) is most …
View article: S193: BMS-986393 (CC-95266), A G PROTEIN–COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)–TARGETED CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1 STUDY
S193: BMS-986393 (CC-95266), A G PROTEIN–COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)–TARGETED CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1 STUDY Open
Background: While chimeric antigen receptor (CAR) T-cell therapies targeting B-cell maturation antigen (BCMA) have shown deep and durable responses in RRMM, new targets are needed as most patients (pts) relapse. GPRC5D, an orphan receptor …
View article: Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma
Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma Open
Summary The prognosis of relapsed/refractory (R/R) anaplastic large cell lymphoma (ALCL) is poor. Large studies evaluating outcomes of allogeneic haematopoietic cell transplantation (allo‐HCT) in systemic R/R ALCL are not available. Using …
View article: Novel Therapies in BCMA-exposed Relapsed/Refractory Multiple Myeloma: The Anti-BCMA Therapy-refractory Patient
Novel Therapies in BCMA-exposed Relapsed/Refractory Multiple Myeloma: The Anti-BCMA Therapy-refractory Patient Open
Multiple myeloma (MM) is a haematologic malignancy resulting from the malignant overgrowth of monoclonal plasma cells in the bone marrow. Nearly 35,000 new cases are expected in the USA each year. In the last two decades there have been ma…
View article: A phase I/<scp>II</scp> study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose‐expansion cohort
A phase I/<span>II</span> study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose‐expansion cohort Open
The maximum tolerated dose of the panobinostat and carfilzomib combination in patients with relapsed/refractory multiple myeloma (RRMM) was not reached in our previous dose‐escalation study. We report additional dose levels in the phase I/…
View article: Latest Developments in Cellular Therapy for Multiple Myeloma
Latest Developments in Cellular Therapy for Multiple Myeloma Open
View article: Managing Tumor Lysis Syndrome in the Era of Novel Cancer Therapies
Managing Tumor Lysis Syndrome in the Era of Novel Cancer Therapies Open
Abstract Tumor lysis syndrome (TLS) is a potentially life-threatening emergency that can develop rapidly after the release of intracellular contents from lysed malignant cells. The advent of novel and targeted therapies that have improved …
View article: Anti–Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease
Anti–Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease Open
Imatinib has clinical activity in chronic graft-versus-host disease (cGVHD), a significant complication of allogeneic hematopoietic cell transplant. Nilotinib is a tyrosine kinase inhibitor that targets the same receptors as imatinib but w…